NeoGenomics, Inc. Overview
Pro stress-test →NeoGenomics operates a network of cancer-focused testing laboratories in the United States and the United Kingdom through two segments: Clinical Services and Advanced Diagnostics. The company specializes in cancer genetics testing and information services, serving oncologists, pathologists, hospitals, and pharmaceutical clients with comprehensive oncology diagnostic solutions.
Strategic Profile
Pro stress-test →The launch of new liquid biopsy products and expanding test offerings position the company to capture market share and benefit from growth in oncology diagnostics demand. 2026 guidance anticipates continued revenue and margin expansion, supported by new product adoption and operational efficiencies, though the company currently operates at a loss as it invests in growth.
Competitive Landscape
Pro stress-test →Competitors include Quest Diagnostics, PathGroup, and Interpace Biosciences. NeoGenomics differentiates through specialized cancer-focused testing, expanding liquid biopsy capabilities, and strong relationships with oncology providers. The company operates in a consolidating diagnostics market where scale and test menu breadth provide competitive advantages.
Industry Context
NeoGenomics, Inc. operates in Clinical Laboratory & Cancer Diagnostics.
Key facts
Founded: 1998 · Headquarters: Fort Myers, US · Employees: 2,500 · Revenue: $727M · Market cap: $1.28B